Login to Your Account

'G'day' for Pathway: $7.5M for PWT33597 Cancer Phase I

By Tom Wall

Thursday, May 26, 2011
Pathway Therapeutics Inc., a San Francisco-based company built largely on research from New Zealand and funding from Australia, raised $7.5 million from two Australian venture investors and will advance its PWT33597 to a Phase I trial for treatment of patients with advanced solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription